se of midazolam in different doses to prevent muscle movements caused by etomidate
Phase 4
Completed
- Conditions
- Health Condition 1: null- Surgery under general anaesthesia
- Registration Number
- CTRI/2017/11/010382
- Lead Sponsor
- niversity College of Medical Sciences and GTB Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 164
Inclusion Criteria
ASA I/II patients, of either sex, undergoing elective surgical procedures under general anaesthesia
Exclusion Criteria
Neuropsychological or neuromuscular disease,
Adrenal cortical dysfunction,
History of allergy to midazolam,
Epilepsy,
Those having received any analgesic or sedative within previous 24 hours
• Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of myoclonic movements after etomidate injectionTimepoint: 60 seconds after etomidate administration
- Secondary Outcome Measures
Name Time Method Severity of myoclonus after etomidate injection <br/ ><br>Changes in heart rate and mean arterial pressure after test drug <br/ ><br>Changes in heart rate and mean arterial pressure after etomidate <br/ ><br>Changes in heart rate and mean arterial pressure after intubation <br/ ><br>Incidence of airway complications e.g. laryngospasm, bronchospasm <br/ ><br>Timepoint: 11 minutes from test drug administration